252 In the index

Trimetazidine TMZ

A heart medication approved in some countries, not the U.S., for chest pain, working by changing how the heart uses energy. It's backed by research where it's approved, and it gained public attention after a doping case involving a young Olympic figure skater.

Also known as Vastarel, Trimetazidina, Trimetazidinum, Dilatan, N9A0A0R9S8, Vastarel MR, RefChem:191732, C01EB15

Effects Endurance

Routes Oral

Legal status Prescription drug

WADA Banned at all times

3D Molecular Structure of C₁₄H₂₂N₂O₃

Drag to rotate · scroll to zoom

Chemistry

Formula: C14H22N2O3
Molar mass: 266.34
CAS: 5011-34-7
PubChem CID: 21109
IUPAC name: 1-[(2,3,4-trimethoxyphenyl)methyl]piperazine
InChIKey: UHWVSEOVJBQKBE-UHFFFAOYSA-N

Reported dosing

Approved label

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 20 mg, 3 times daily (immediate-release) or 35 mg twice daily (modified-release)

Reported range 20-70 mg/day

Route Oral

Frequency 2-3 times daily depending on formulation

Duration Chronic/ongoing (as prescribed, where approved)

Approved in some countries (not the US) for angina; gained public attention after a doping case involving a young Olympic figure skater. Not FDA-approved.

Where this comes from International prescribing information; anti-doping case literature

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.